A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

475 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-01

Study Completion Date

2019-08-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents

NCT00963937

Migraine Disorders

COMPLETED PHASE3

Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

NCT03185143

Migraine With and Without Aura

COMPLETED PHASE2/PHASE3

Efficacy and Safety of Zolmitriptan by Sublingual Administration

NCT03377257

Cluster Headache

UNKNOWN PHASE4

Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment

NCT01814189

Migraine With Aura Migraine Without Aura

COMPLETED PHASE3

Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

NCT00432237

Migraine

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Multicenter, Randomized, Double-Blind, Comparator-Controlled, Placebo-Controlled Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain, With or Without Aura, and the Prevention of Migraine-Associated Nausea and Vomiting (MANV)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine Pain Nausea Vomiting Aura

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Double Blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1: CL-H1T

Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine hydrochloride 18.75mg)

Group Type EXPERIMENTAL

Arm 1: CL-H1T

Intervention Type DRUG

One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)

Arm 2: CL-H1T

Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5mg)

Group Type EXPERIMENTAL

Arm 2: CL-H1T

Intervention Type DRUG

One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)

Arm 3: Sumatriptan succinate 100 mg

Maximum dose within a 24 hour period: One capsule of sumatriptan succinate 100mg

Group Type EXPERIMENTAL

Arm 3: Sumatriptan Succinate 100 mg capsule

Intervention Type DRUG

One capsule of sumatriptan succinate 100 mg

Arm 4: Promethazine HCl 18.75 mg

Maximum dose within a 24 hour period: One capsule of promethazine HCl 18.75mg

Group Type EXPERIMENTAL

Arm 4: Promethazine HCl 18.75 mg

Intervention Type DRUG

One capsule of promethazine HCl 18.75 mg

Arm 5: Promethazine HCl 37.5 mg

Maximum dose within a 24 hour period: One capsule of promethazine HCl 37.5mg

Group Type EXPERIMENTAL

Arm 5: Promethazine HCl 37.5 mg

Intervention Type DRUG

One capsule of promethazine HCl 37.5 mg

Arm 6: Placebo

Maximum dose within a 24 hour period: One capsule of placebo

Group Type EXPERIMENTAL

Placebo

Intervention Type OTHER

One capsule of placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arm 1: CL-H1T

One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)

Intervention Type DRUG

Arm 2: CL-H1T

One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)

Intervention Type DRUG

Arm 3: Sumatriptan Succinate 100 mg capsule

One capsule of sumatriptan succinate 100 mg

Intervention Type DRUG

Arm 4: Promethazine HCl 18.75 mg

One capsule of promethazine HCl 18.75 mg

Intervention Type DRUG

Arm 5: Promethazine HCl 37.5 mg

One capsule of promethazine HCl 37.5 mg

Intervention Type DRUG

Placebo

One capsule of placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

sumatriptan succinate 90mg/promethazine HCl 18.75mg sumatriptan succinate 90mg/promethazine HCl 37.5mg Sumatriptan succinate 100 mg Promethazine HCl 18.75 Promethazine HCl 37.5

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to understand and willing to give written informed consent and authorize the Health Insurance Portability and Accountability Act (HIPAA) prior to entering the study.
2. Men and women with episodic migraine who meet the criteria of the International Headache Society's Headache Classification Committee for migraine with or without aura.
3. Between the ages of 18 and 75 years of age, inclusive.
4. A history of episodic migraine for at least 1 year.
5. Maximal frequency of 8 migraine attacks per month; minimum frequency of 2 migraine attacks per month; at least 48 hours of headache-free time between migraine attacks.
6. Maximum total headache days of 14 per month.
7. History of migraine headache with nausea ≥ 50% of the time.
8. Able and willing to complete an electronic diary (eDiary) to record the details of a migraine attack treated with investigational treatment.
9. Able to swallow a capsule whole.
10. Report headache on the Headache Pain Scale at Baseline before treatment.
11. Report the presence of nausea on the Nausea Scale at Baseline before treatment.
12. Women of childbearing potential (WOCBP) must practice an acceptable method of birth control (acceptable methods of birth control in this study include: surgical sterilization, intrauterine device, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy, or a double-barrier method \[condom or diaphragm with spermicide\]). Use of intrauterine devices and hormonal contraceptives must begin at least 8 weeks prior to Screening.
13. Willing and able to comply with the protocol requirements for the duration of the study.

Exclusion Criteria

1. A clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation. Such conditions may include cardiac, respiratory, hepatic, renal or metabolic diseases, peripheral vascular disease, any systemic disease, acute infection, or neurological disease (including Parkinson's Disease or other condition associated with a movement disorder), current malignancy or recent history (within 5 years) of malignancy (other than squamous cell or basal cell carcinoma) or any medical condition that, in the opinion of the Investigator, makes the subject unsuitable for participation in the study.
2. A positive saliva screen for alcohol or a positive urine drug screen for cocaine, narcotics, benzodiazepines, opioids, tetrahydrocannabinol (THC), barbiturates, amphetamines, or any prescription drugs unless such a positive result can be explained by stated concomitant medications.
3. Regularly smoke cigarettes or use opiate analgesic drugs, benzodiazepines, ergot containing drugs, alcohol, THC, or other drugs of abuse that, at the discretion of the Investigator, may interfere with the evaluation of the endpoints in the trial.
4. Unstable use of prophylactic migraine medication (eg, change of dose or type of medication) during the 30 days prior to Screening Visit.
5. Subjects using monoamine oxidase-A (MAO-A) inhibitors and who cannot be washed out.
6. Subjects using selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, THC, or systemic corticosteroids over the past month prior to the Screening Visit.
7. Daily use of antipsychotics at least 15 days prior to randomization.
8. Medication overuse:

1. Opioids for headache ≥ 10 days during the 90 days prior to Screening Visit;
2. Combination medications that contain an opioid and/or barbiturate (eg, Fiorinal®) ≥ 10 days during the 90 days prior to Screening Visit.
3. Nonsteroidal anti-inflammatory drugs (NSAIDs) or other simple medications ˃ 14 days a month during the 90 days prior to Screening Visit.
4. Triptans or ergots ≥ 10 days a month during the 90 days prior to Screening Visit.
9. Use of mini prophylaxis for menstrual migraine.
10. History of allergic reaction or drug sensitivity to any triptans.
11. History of allergic reaction or drug sensitivity to promethazine.
12. History of allergic reaction or drug sensitivity to acetaminophen.
13. History of extrapyramidal reaction (eg, akathisia or dystonia) to neuroleptic treatments.
14. Subjects who are pregnant (positive urine hCG: Human chorionic gonadotropin test at Screening Visit) or breastfeeding.
15. Use of experimental or investigational treatments and/or participation in drug clinical studies within the 6 months before the Screening Visit.
16. Subjects who are employees of the Sponsor.
17. Relatives of, or staff directly reporting to, the Investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No